On the afternoon of October 25, the plenary session of 2025 International Biomedical Industry Innovation Conference Beijing Forum, themed “Innovation Without Borders, Health for a Shared Future,” was held. Yin Li, Secretary of the CPC Beijing Municipal Committee, and Lei Haichao, Head of the National Health Commission (NHC), delivered speeches. Yin Yong, Deputy Secretary of the CPC Beijing Municipal Committee and Mayor of Beijing, attended the event.

In his speech, Yin Li said that the Chinese government attaches great importance to the advancement of medical technologies and the development of the medical industry. The 20th CPC Central Committee, at its Fourth Plenary Session, outlined the goals and tasks for China’s economic and social development during the 15th Five-Year Plan period, including arrangements for the biomedical industry development, which will inject new momentum into international health cooperation. Beijing is a pacesetter for innovation in China’s biomedical industry, with abundant resources in education, science and technology, and talent. The city has established a leadership in fields such as synthetic biology, cell and gene therapy, and digital healthcare. The pharmaceutical and health sector continues to see robust development, supported by the two editions of 32 support measures for high-quality development of innovative medical products in Beijing over the past two years. The industry’s total scale has now surpassed one trillion yuan. Looking forward, Beijing will build a modern biomedical industrial cluster through the efforts of building itself into an international center for science and technology innovation. The city is ready to work with all parties to jointly conduct research and development, achieve new technological breakthroughs, and support close collaboration among universities, research institutes, hospitals, and innovative enterprises in Beijing. Efforts will focus on the co-development and sharing of scientific equipment, pilot-scale testingplatforms, and clinical trials, as well as the application of new technologies such as artificial intelligence (AI) to continuously improve pharmaceutical R&D efficiency. Beijing will accelerate the application of innovation achievements to promote health, take advantage of policies such as the pilot zone for the special provision of rare disease drugs, optimize the approval process for innovative drugs and full-process services, and improve multi-level medical security systems to enhance the accessibility and affordability of vaccines and new drugs. Efforts will also be made tostrengthen collaboration in the pharmaceutical industry, cultivate new growth drivers, foster a favorable industrial ecosystem, and enhance policy support, resource input, and intellectual property protection. We will focus on the development of the Bio-Park and other industrial parks, and keep upgrading industrial and supply chains. We will take measures todeepen international exchange and cooperation, advance progress in governance, implement the Global Governance Initiative (GGI), enhance experience sharing in healthcare services, public health, and healthy aging, and strengthen the safety management and use of new drugs, technologies, and equipment, contributing Beijing’s strength to the advancement of global health.

Lei Haichao said that China is advancing the Healthy China Initiative across the board and implementing a health-first development strategy. China focuses on primary-level healthcare and prevention while continuing to deepen reforms of the healthcare system and support scientific and technological innovation in the health sector. The Fourth Plenary Session of the 20th CPC Central Committee has set out key tasks, including accelerating the implementation of the Healthy China Initiative and promoting high-quality population development, providing biomedical companies with broad development prospects, opportunities, and huge market potential in China. Looking forward, we are ready to work with all parties to maintain openness and inclusivity, jointly foster an innovative and collaborative environment, expand cooperation, share innovation resources, solve medical challenges, and jointly improve global health. China will continue to seek mutual benefit and win-win results, promote innovation in the biomedical industry, and encourage enterprises to increase investment and R&D in China, so as to develop new technologies, high-quality products, and health-promoting solutions for the world. China will further improve mechanisms for coordinated development and governance across healthcare, health insurance, and pharmaceuticals, strengthen government-business exchanges, and facilitate the deep integration of technological and industrial innovation. Efforts will also be made to pursue shared development, narrow global health gaps, share resources with international partners, and jointly advance health development globally.

During the forum, Yin Yong presented “service packages” to executives of key medical companies and issued the Certificate of Recognition to advisors of the BioPark International Strategic Advisory Committee. Speeches were delivered by Pascal Soriot, global CEO of AstraZeneca; Wang Jinnan, Vice Chairman of the Central Committee of the Chinese Peasants and Workers Democratic Party (CPWDP) and Chairman of the Beijing Municipal Committee, CPWDP; Li Tao, Deputy Commissioner of the National Healthcare Security Administration; and Xu Jinghe, Deputy Commissioner of the National Medical Products Administration. At the event, the planning proposal for the BioPark, results of Beijing’s measures to support the high-quality development of innovative medical products, and key projects in the pharmaceutical and health industry were released.

Attendees included Jin Wei and Zhao Lei, leaders from the Beijing Municipal Government; Zeng Jin, Secretary General of the Beijing Municipal Government; officials from relevant national ministries and Beijing municipal departments; as well as representatives from domestic and international industry organizations, universities, research institutes, hospitals, and enterprises.